Home
HelpTest Code HPP Pancreatic Polypeptide, Plasma
Reporting Name
Pancreatic Polypeptide, PUseful For
Detecting pancreatic endocrine tumors
Assessing vagal nerve function after meal or sham feeding
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
Plasma EDTAOrdering Guidance
This test should not be requested on patients who have recently received radioactive materials.
Necessary Information
Patient's age must be provided.
Specimen Required
Patient Preparation: Fasting (8 hours)
Collection Container/Tube: Lavender top (EDTA)
Submission Container/Tube: Plastic vial
Specimen Volume: 3 mL
Collection Instructions:
1. Place specimen on wet ice and keep cold at all times following collection.
2. Centrifuge (refrigerated centrifuge is not required) and aliquot plasma into plastic vial. Freeze immediately.
Specimen Minimum Volume
0.35 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Plasma EDTA | Frozen | 90 days |
Reference Values
0-19 years: Not established
20-29 years: <228 pg/mL
30-39 years: <249 pg/mL
40-49 years: <270 pg/mL
50-59 years: <291 pg/mL
60-69 years: <312 pg/mL
70-79 years: <332 pg/mL
≥80 years: Not established
Day(s) Performed
Monday, Wednesday
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
83519
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| HPP | Pancreatic Polypeptide, P | 2721-9 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 8014 | Pancreatic Polypeptide, P | 2721-9 |
Interpretation
High levels of pancreatic polypeptide may be seen in pancreatic endocrine tumors, diabetes, and a nonfasting state. Markedly elevated levels may be seen in some pancreatic exocrine tumors.
A normal response to a sham feeding consists of a rapid pancreatic polypeptide rise over baseline followed by a return to baseline. With vagal damage, no increase over baseline is seen.
Clinical Reference
1. Panzuto F, Severi C, Cannizzaro R, et al: Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Invest. 2004 Jan;27(1):6-11
2. Brimnes Damholt M, Rasmussen BK, Hilsted L, et al: Basal serum pancreatic polypeptide is dependent on age and gender in an adult population. Scand J Clin Lab Invest. 1997 Dec;57(8):695-702
3. Escobar H, Jushnir M, Ray J, et al: Measurement of pancreatic polypeptide and its peptide variant in human serum and plasma by immunocapture-liquid-chromatography-tandem mass spectrometry. Reference intervals and practical assay considerations. Biochem Physiol. 2014 Aug;3:140. doi: 10.4172/2168-9652.1000140
4. Balaji N, Crookes P, Banki F, et al: A Safe and Noninvasive Test for Vagal Integrity Revisited. Arch Surg. 2002 Aug;137(8):954-959
Report Available
4 to 8 daysMethod Name
Radioimmunoassay (RIA)
Forms
If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.